Scienmag

FEBRUARY 10, 2021

Credit: Lei Dong, Nanjing University Scientists from Nanjing University and the University of Macau have devised a new approach to extend the survival of transplanted probiotics in vivo, enhancing the efficacy of cancer chemo-/immunotherapies in mice.

In-Vivo 69

In-Vivo Scientist Engineer Medicine 69

BioTech 365

MARCH 9, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Scientists discover dynamic trimolecular G-quadruplex.As

Scientist 40

Scientist In-Vivo In-Vitro DNA 40

Pharmaceutical Technology

FEBRUARY 13, 2023

Best practice is to also consider the ‘developability’ of the lead compounds in conjunction with any evidence of potential in-vivo activity, by taking a holistic approach. With all this in mind, how do drug developers know which strategy and approach is right for their molecule at this early stage?

Development 130

Development In-Vivo Drugs Clinical Trials 130

Scienmag

NOVEMBER 16, 2020

Singapore scientists uncover potential role of long non-coding RNAs in pancreatic cancer Credit: From Figure 4 in Liu, S., Wnt-regulated lncRNA discovery enhanced by in vivo identification and CRISPRi functional validation. Harmston, N., Glaser, T.L. Genome Med 12, 89 (2020).

In-Vivo 53

In-Vivo RNA DNA Genome 53

Camargo

DECEMBER 22, 2021

For products that have an US RLD counterpart, FDA may waive in vivo study requirements, depending on the drug formulation, proposed indication, active ingredients, solubility, permeability, and other factors. However, they may generate undifferentiated labels that are not conducive to commercial success. Clinical Pharmacology.

Bioequivalency 169

Bioequivalency Production Genotoxicity In-Vivo 169

Scienmag

FEBRUARY 22, 2021

Using innovative in vivo imaging approaches, scientists […]. Some make use of the immune system to act and belong to a class of treatment called “immunotherapies.” ” But how do these antibodies function within the tumor? And how can we hope to improve their efficacy?

In-Vivo 41

In-Vivo Antibody Scientist Allergies 41

Scienmag

OCTOBER 23, 2020

Oncotarget recently published a novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe four novel formats for the L19-IL2 fusion Credit: Correspondence to – Dario Neri – dario.neri@pharma.ethz.ch

Recombinant Antibody 53

Recombinant Antibody Protein Antibody In-Vivo 53

XTalks

OCTOBER 1, 2020

Leaving academia for industry is a route that academic scientists and professors did not traditionally pursue in the past due to perceived differences in skillsets, experiences and even associated stigmas. WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation.

Scientist 52

Scientist In-Vitro Research Life Science 52

Camargo

FEBRUARY 10, 2021

Drug development is an extremely cumbersome process, requiring the testing of an agent from in vitro studies to in vivo studies to in silico modeling. Given that it can take up to 20 years for a final product to be approved, it is unsurprising that drug attrition rates are very high. Approaches to Pharmacokinetic Analysis.

Production 133

Production Bioavailability In-Vivo In-Vitro 133

pharmaphorum

AUGUST 5, 2021

The combination of MDC’s in vivo imaging and infrastructure, with WMIC’s heritage in radiochemistry, further strengthens the national PET Network, which has been established across the UK by MDC and leading academic centres of excellence. ” Find out more about MDCs PET Imaging expertise here.

Medicine 52

Medicine In-Vivo Packaging Packaging 52

pharmaphorum

APRIL 6, 2021

Shiva Kazerounian , Associate Director & Principal Scientist – In Vivo Pharmacology, Berg Health. There is a crucial need to progress candidates from bench to bedside. With that in mind, I am delighted to share the official agenda and speaker faculty for the 9th PREDiCT: Tumor Models Cell Therapy Summit.

In-Vivo 52

In-Vivo Clinical Design Scientist Medicine 52

XTalks

APRIL 22, 2022

Receptor occupancy assays have been developed and applied in both nonclinical and clinical studies to provide insight into PK/PD relationships so far,” said Andre Olsson, PhD, Senior Scientist, Flow Cytometry at the global contract research organization (CRO) Medpace. What is Flow Cytometry?

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

The Pharma Data

NOVEMBER 22, 2020

Scientists in Israel have used the CRISPR Cas-9 gene editing system to destroy cancerous cells in mice without damaging other cells. To conduct the research, the scientists used hundreds of mice with two of the most aggressive forms of cancer: glioblastoma and metastatic ovarian cancer. Photo courtesy of Science Advances.

Gene Editing 52

Gene Editing DNA Genome Genomics 52

The Pharma Data

NOVEMBER 10, 2020

This model has the benefit of giving companies direct oversight of their in vivo studies, allowing them to move faster while operationalizing every dollar of their seed financing. Photo courtesy of Mispro. There’s an emerging business model in biotech town, and it’s called the Contract Vivarium (CV).

Marketing 52

Marketing In-Vivo Scientist Research 52

pharmaphorum

APRIL 29, 2021

To achieve this, the agenda will allow delegates to: Explore the translation of BBB-penetrating antibodies to non-human primates , and new possibilities for in vivo brain imaging of antibody neuropharamacokinetics. A Meeting Point for the Field’s Experts. 3-day Conference | June 28-30, 2021. About Hanson Wade.

Drug Delivery 52

Drug Delivery Gene Therapy In-Vivo Antibody 52

Delveinsight

FEBRUARY 11, 2021

The scientists analyzed samples from patients with the most common pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC). The scientists analyzed samples from patients with the most common pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC). Enhancing the response to immuno-oncology in pancreatic cancer.

Gene Therapy 52

Gene Therapy Gene Immune Response In-Vivo 52

Delveinsight

FEBRUARY 25, 2021

Electroporation is used for ex vivo delivery of therapies to blood and immune cells. The company’s in vivo therapies reach the eye and central nervous system via adeno-associated viruses, while its liver therapies employ lipid nanoparticles (LNPs). Beam employs three approaches to deliver its genetic medicines to cells.

DNA 52

DNA In-Vivo Genetics Medicine 52

The Pharma Data

NOVEMBER 24, 2020

Fidelta, located in R&D facilities in Croatia, currently has 181 employees, including more than 150 scientists. Selvita expects the acquisition will help the company “build a competitive advantage” in key business areas, including DMPK, in vivo pharmacology as well as toxicology. million, or over $37 million in U.S.

Drugs 52

Drugs In-Vivo Marketing Development 52

The Pharma Data

OCTOBER 15, 2020

F4 Pharma — In order to help F4 Pharma advance its COVID-19 asset FX06 and to provide strategic guidance, F4 Pharma has appointed a scientific advisory board consisting of clinicians and scientists. The Advance awards recognize the work of remarkable global Australians making an extraordinary impact worldwide.

In-Vivo 52

In-Vivo Business Development Manufacturing Development 52

FDA Law Blog

FEBRUARY 2, 2023

The law defines this term to mean “a test conducted in vitro, in silico, or in chemico, or a nonhuman in vivo test that occurs before or during the clinical trial phase of the investigation of the safety and effectiveness of a drug.” Tobolowsky & Charles G. FDORA § 3209(a)(1). FDORA § 3209(a)(2). 42 U.S.C. § 262(k)(2)(A)(i)(I).

Clinical Trials 64

Clinical Trials Clinical Trials In-Vivo In-Vitro 64

XTalks

SEPTEMBER 20, 2024

Such challenges highlight a significant unmet need and call for further advancements in the field. Vittoria Biotherapeutics is a clinical-stage cell therapy company that incorporates the latest advancements in cell therapy and gene editing with a unique approach that potentially overcomes some of the issues with this therapeutic modality.

Gene Editing 52

Gene Editing Manufacturing Gene In-Vivo 52

The Pharma Data

JANUARY 11, 2021

Scientists at the FDA demonstrated CN Bio’s PhysioMimix MPS technology accurately models drug metabolism and detects compounds known to be toxic to humans. Liver toxicity is a major safety concern during drug discovery and development, with the potential to terminate clinical trials and result in expensive program failures.

In-Vivo 40

In-Vivo Drugs Clinical Trials Clinical Trials 40

The Pharma Data

JANUARY 27, 2021

Hayden, CEO of Prilenia and world-renowned scientist in Huntington’s Disease research , commented: “The design of the PROOF-HD study is based on strong scientific and clinical data, including in vivo target engagement for the selected dose, prior clinical efficacy results and extensive long-term safety data in our target population.

Clinical Trials 40

Clinical Trials Clinical Trials Trials In-Vivo 40

Roots Analysis

AUGUST 23, 2024

This adaptability was clear in coronavirus vaccine development using mRNA technology; after researchers had sequenced the virus’s RNA during January 2020, scientists were able create viable vaccine candidates within just months. This modern marvel wasn’t just used against COVID-19 but can be tailored now to fight any number of diseases.

Protein 40

Protein Vaccination Vaccine Immune Response 40

Roots Analysis

OCTOBER 19, 2023

Bacteria plays a crucial role in maintaining the ecosystem balance. However, there are few species of bacteria that can cause several infectious diseases ( such as strep throat, salmonellosis, tuberculosis, whooping cough ). These are mainly transmitted through air, water, living organisms, and food.

Bacteria 40

Bacteria Production In-Vivo In-Vitro 40

pharmaphorum

SEPTEMBER 15, 2022

Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it to build on its foundational insights into precision in vivo engineering technology. The research was undertaken by world-renowned mRNA and cell therapy scientists and clinicians at the University of Pennsylvania.

In-Vivo 105

In-Vivo Engineer Scientist Life Science 105

XTalks

NOVEMBER 3, 2023

The scientists on the advisory committee were particularly focused on the CRISPR gene editing technology itself and how companies like Vertex that are developing CRISPR-based therapies are ensuring their treatments are not making off-target gene edits. CRISPR works as genetic scissors to edit parts of the genome.

Gene Therapy 59

Gene Therapy Gene Gene Editing In-Vivo 59

The Pharma Data

NOVEMBER 10, 2020

Hydrogen-Oxygen Inhalation for Treatment of COVID-19, a monograph concluding China’s experience in the fight against COVID-19, reports that Hydrogen Oxygen Generator with Nebulizer is effective in treating patients with COVID-19 coronavirus. . . SHANGHAI , Nov. SHANGHAI , Nov.

Medicine 52

Medicine In-Vivo Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 20, 2020

. PARTNERSHIP LEVERAGES COMPLEMENTARY STRENGTHS OF IN SILICO, IN VITRO AND IN VIVO ANTIBODY DISCOVERY IN A RANGE OF INDICATIONS. ” ABOUT ALLOY THERAPEUTICS Alloy Therapeutics is a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all.

Antibody 52

Antibody In-Vivo In-Vitro Scientist 52

Pharmaceutical Technology

FEBRUARY 23, 2023

Our chemists and formulation scientists review the properties of new drug candidates and “work their magic” to develop formulations that improve the exposure profile of the compound. Quotient Sciences helps biotech and pharma customers in the development and optimization of drug products.

Development 246

Development Drugs Bioavailability In-Vivo 246